Loading...

ABIOMED

Nasdaq:ABMD
Snowflake Description

Flawless balance sheet with outstanding track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ABMD
Nasdaq
$12B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • ABIOMED has significant price volatility in the past 3 months.
ABMD Share Price and Events
7 Day Returns
3.2%
NasdaqGS:ABMD
-0.6%
US Medical Equipment
-0.7%
US Market
1 Year Returns
-31.3%
NasdaqGS:ABMD
11.7%
US Medical Equipment
3%
US Market
ABMD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ABIOMED (ABMD) 3.2% 1.5% -27.5% -31.3% 168.6% 1134.5%
US Medical Equipment -0.6% -0.4% -0.6% 11.7% 59.4% 92.5%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • ABMD underperformed the Medical Equipment industry which returned 11.7% over the past year.
  • ABMD underperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
ABMD
Industry
5yr Volatility vs Market

Value

 Is ABIOMED undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ABIOMED to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ABIOMED.

NasdaqGS:ABMD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:ABMD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.9
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.896 (1 + (1- 21%) (0%))
0.93
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.93 * 5.96%)
8.27%

Discounted Cash Flow Calculation for NasdaqGS:ABMD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ABIOMED is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:ABMD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.27%)
2019 187.60 Analyst x1 173.27
2020 256.40 Analyst x1 218.72
2021 314.01 Est @ 22.47% 247.39
2022 365.96 Est @ 16.55% 266.29
2023 411.35 Est @ 12.4% 276.45
2024 450.43 Est @ 9.5% 279.58
2025 484.07 Est @ 7.47% 277.51
2026 513.34 Est @ 6.05% 271.80
2027 539.28 Est @ 5.05% 263.72
2028 562.77 Est @ 4.36% 254.18
Present value of next 10 years cash flows $2,528.90
NasdaqGS:ABMD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $562.77 × (1 + 2.73%) ÷ (8.27% – 2.73%)
$10,430.32
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $10,430.32 ÷ (1 + 8.27%)10
$4,710.90
NasdaqGS:ABMD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,528.90 + $4,710.90
$7,239.80
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $7,239.80 / 45.12
$160.45
NasdaqGS:ABMD Discount to Share Price
Calculation Result
Value per share (USD) From above. $160.45
Current discount Discount to share price of $260.48
= -1 x ($260.48 - $160.45) / $160.45
-62.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of ABIOMED is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ABIOMED's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ABIOMED's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ABMD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $5.77
NasdaqGS:ABMD Share Price ** NasdaqGS (2019-05-17) in USD $260.48
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 38.66x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ABIOMED.

NasdaqGS:ABMD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ABMD Share Price ÷ EPS (both in USD)

= 260.48 ÷ 5.77

45.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ABIOMED is overvalued based on earnings compared to the US Medical Equipment industry average.
  • ABIOMED is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does ABIOMED's expected growth come at a high price?
Raw Data
NasdaqGS:ABMD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 45.16x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
10.3%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.23x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

NasdaqGS:ABMD PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 45.16x ÷ 10.3%

4.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ABIOMED is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on ABIOMED's assets?
Raw Data
NasdaqGS:ABMD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $20.76
NasdaqGS:ABMD Share Price * NasdaqGS (2019-05-17) in USD $260.48
United States of America Medical Equipment Industry PB Ratio Median Figure of 182 Publicly-Listed Medical Equipment Companies 4.5x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGS:ABMD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ABMD Share Price ÷ Book Value per Share (both in USD)

= 260.48 ÷ 20.76

12.55x

* Primary Listing of ABIOMED.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ABIOMED is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess ABIOMED's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. ABIOMED has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ABIOMED expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ABIOMED expected to grow at an attractive rate?
  • ABIOMED's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • ABIOMED's earnings growth is positive but not above the United States of America market average.
  • ABIOMED's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ABMD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ABMD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 10.3%
NasdaqGS:ABMD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 18.8%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.5%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ABMD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ABMD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-03-31 1,741 415 2
2022-03-31 1,414 346 5
2021-03-31 1,150 271 9
2020-03-31 927 209 9
NasdaqGS:ABMD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 769 259
2018-12-31 737 238 222
2018-09-30 690 220 190
2018-06-30 641 203 165
2018-03-31 594 193 112
2017-12-31 544 173 90
2017-09-30 505 151 92
2017-06-30 475 125 77
2017-03-31 445 115 52
2016-12-31 415 100 48
2016-09-30 386 92 43
2016-06-30 359 92 42

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ABIOMED's earnings are expected to grow by 10.3% yearly, however this is not considered high growth (20% yearly).
  • ABIOMED's revenue is expected to grow by 18.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ABMD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from ABIOMED Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ABMD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-03-31 9.74 10.88 8.59 2.00
2022-03-31 7.75 8.85 6.89 4.00
2021-03-31 5.97 7.17 5.16 8.00
2020-03-31 4.60 5.13 4.32 8.00
NasdaqGS:ABMD Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 5.77
2018-12-31 4.96
2018-09-30 4.28
2018-06-30 3.72
2018-03-31 2.54
2017-12-31 2.05
2017-09-30 2.11
2017-06-30 1.76
2017-03-31 1.21
2016-12-31 1.12
2016-09-30 1.01
2016-06-30 0.99

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • ABIOMED is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess ABIOMED's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ABIOMED has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ABIOMED performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ABIOMED's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ABIOMED has delivered over 20% year on year earnings growth in the past 5 years.
  • ABIOMED's 1-year earnings growth exceeds its 5-year average (130.9% vs 35.9%)
  • ABIOMED's earnings growth has exceeded the US Medical Equipment industry average in the past year (130.9% vs 31.9%).
Earnings and Revenue History
ABIOMED's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ABIOMED Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ABMD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 769.43 259.02 321.55 93.50
2018-12-31 736.79 221.90 315.76 89.07
2018-09-30 690.25 190.49 302.09 82.31
2018-06-30 641.29 164.86 283.28 78.73
2018-03-31 593.75 112.17 262.73 73.96
2017-12-31 543.99 90.22 247.33 68.10
2017-09-30 504.65 92.21 234.71 66.91
2017-06-30 474.78 76.58 227.72 65.98
2017-03-31 445.30 52.12 218.15 64.80
2016-12-31 414.58 48.22 203.31 63.50
2016-09-30 385.70 43.34 191.23 60.76
2016-06-30 359.11 42.20 177.97 54.13
2016-03-31 329.54 38.15 164.26 48.71
2015-12-31 303.14 126.02 152.44 44.36
2015-09-30 279.35 128.15 140.73 39.40
2015-06-30 254.93 124.26 130.35 36.46
2015-03-31 230.31 113.69 125.73 35.46
2014-12-31 210.49 18.44 119.91 33.68
2014-09-30 194.68 10.15 114.14 33.24
2014-06-30 187.08 7.37 110.88 32.48
2014-03-31 183.64 7.35 107.25 30.71
2013-12-31 176.88 7.47 102.42 29.61
2013-09-30 168.94 5.76 99.00 28.09
2013-06-30 162.01 10.17 91.24 26.22
2013-03-31 158.12 15.01 84.23 25.65
2012-12-31 151.79 13.84 80.36 26.06
2012-09-30 145.74 14.08 76.60 25.94
2012-06-30 137.80 9.21 74.49 26.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • ABIOMED has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • ABIOMED used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • ABIOMED has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess ABIOMED's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ABIOMED has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ABIOMED's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ABIOMED's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ABIOMED is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ABIOMED's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ABIOMED's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • ABIOMED has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ABIOMED Company Filings, last reported 1 month ago.

NasdaqGS:ABMD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 936.89 0.00 491.70
2018-12-31 851.53 0.00 458.16
2018-09-30 792.95 0.00 410.45
2018-06-30 723.36 0.00 360.52
2018-03-31 689.52 0.00 362.25
2017-12-31 632.48 0.00 301.25
2017-09-30 604.89 15.96 263.20
2017-06-30 567.04 16.15 251.41
2017-03-31 452.07 16.34 229.95
2016-12-31 417.38 16.52 240.71
2016-09-30 398.44 16.70 232.95
2016-06-30 377.33 0.00 223.17
2016-03-31 368.78 0.00 212.05
2015-12-31 345.53 0.00 196.19
2015-09-30 331.10 0.00 175.51
2015-06-30 308.05 0.00 154.92
2015-03-31 291.56 0.00 131.96
2014-12-31 195.72 0.00 113.42
2014-09-30 175.54 0.00 95.46
2014-06-30 170.35 0.00 87.20
2014-03-31 168.35 0.00 76.58
2013-12-31 160.46 0.00 79.58
2013-09-30 150.70 0.00 71.07
2013-06-30 141.31 0.00 67.45
2013-03-31 137.08 0.00 76.71
2012-12-31 136.05 0.00 85.74
2012-09-30 140.67 0.00 88.98
2012-06-30 130.52 0.00 81.22
  • ABIOMED has no debt.
  • ABIOMED had no debt 5 years ago.
  • ABIOMED has no debt, it does not need to be covered by operating cash flow.
  • ABIOMED has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess ABIOMED's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ABIOMED has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ABIOMED's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ABIOMED dividends.
If you bought $2,000 of ABIOMED shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ABIOMED's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ABIOMED's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ABMD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ABMD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-03-31
2022-03-31
2021-03-31
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ABIOMED has not reported any payouts.
  • Unable to verify if ABIOMED's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ABIOMED's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ABIOMED has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ABIOMED's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ABIOMED afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ABIOMED has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ABIOMED's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Minogue
COMPENSATION $10,304,727
AGE 51
TENURE AS CEO 15.1 years
CEO Bio

Mr. Michael R. Minogue, also known as Mike, has been Chief Executive Officer and President of ABIOMED Europe GmbH since April 2004. Mr. Minogue has been Chief Executive Officer, President and Director of ABIOMED, Inc. since April 2004 and has been its Chairman since June 15, 2005. Previously, Mr. Minogue spent twelve years at GE Healthcare, a subsidiary of General Electric, where he holds three patents and developed expertise in sales, marketing, product development and software/service operations around diagnostic imaging and treatment of cancer and cardiovascular disease. He was a Member of Board of Managers at Bioventus LLC since June 2016 until October 25, 2018. From 1997 to 2004, Mr. Minogue held various positions at GE, including General Manager for the Global Positron Emission Technology Business, General Manager, Americas Cardiology & IT Sales and General Manager of Global Installed Base. Mr. Minogue served as Vice President and General Manager of Americas Sales and Marketing for GE Medical Systems Information Technology. He is a seasoned business executive with more than two decades of experience. He has been Chairman at ABIOMED Europe GmbH since April 2004 and has been its Director since April 2004. He served as Chairman at MassMEDIC and has ten years of service on its Board of Directors. He has been Director at Insulet Corporation since August 10, 2017. He served as a Director of World Heart Corp. from October 2008 to September 18, 2009 and LifeCell Corporation from October 1, 2005 to May 2008. Mr. Minogue is also one of the co-founders and Chairman of the MedTech and BioTech Veterans Program. He serves as a Director of Advanced Medical Technology Association. Mr. Minogue is the Co-Founder and Chairman of the Mentoring Veterans Program (MVPvets), a nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the life sciences industries. He serves on the Board of Directors of AdvaMed. He serves as the Chairman of the Medical Device Innovation Consortium and serves as the Chairman of the Governor's Advisory Council on Veterans Services for the Commonwealth of Massachusetts. He served as an Infantry officer in the U.S. Army for four years, which included multiple distinctions, including Airborne Ranger, Desert Storm Veteran and he was awarded the Bronze Star. Mr. Minogue received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his Master of Business Administration from the University of Chicago.

CEO Compensation
  • Mike's compensation has been consistent with company performance over the past year.
  • Mike's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the ABIOMED management team in years:

10.8
Average Tenure
52.5
Average Age
  • The average tenure for the ABIOMED management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mike Minogue

TITLE
Chairman
COMPENSATION
$10M
AGE
51
TENURE
15.1 yrs

David Weber

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
57
TENURE
12.1 yrs

Michael Howley

TITLE
VP & GM of Global Sales
COMPENSATION
$2M
AGE
54
TENURE
10.2 yrs

William Bolt

TITLE
Executive Officer
COMPENSATION
$2M
AGE
66
TENURE
16.3 yrs

Ian McLeod

TITLE
VP & Corporate Controller
COMPENSATION
$1M
TENURE
11.5 yrs

Todd Trapp

TITLE
CFO & VP
AGE
47
TENURE
1.1 yrs

Thorsten Siess

TITLE
Chief Technology Officer

Ingrid Ward

TITLE
Director of Investor Relations
TENURE
4.7 yrs

Marc Began

TITLE
VP, General Counsel & Secretary
TENURE
1.3 yrs

Andrew Greenfield

TITLE
VP & Chief Commercial Officer
COMPENSATION
$536K
AGE
45
Board of Directors Tenure

Average tenure and age of the ABIOMED board of directors in years:

6.4
Average Tenure
65.5
Average Age
  • The tenure for the ABIOMED board of directors is about average.
Board of Directors

Mike Minogue

TITLE
Chairman
COMPENSATION
$10M
AGE
51
TENURE
13.9 yrs

Dorothy Puhy

TITLE
Lead Director
COMPENSATION
$295K
AGE
66
TENURE
13.6 yrs

Marty Sutter

TITLE
Director
COMPENSATION
$267K
AGE
63
TENURE
11 yrs

Paul Thomas

TITLE
Director
COMPENSATION
$270K
AGE
62
TENURE
8 yrs

Chris Van Gorder

TITLE
Director
COMPENSATION
$265K
AGE
65
TENURE
3.3 yrs

Eric Rose

TITLE
Director
COMPENSATION
$260K
AGE
67
TENURE
4.8 yrs

Jeannine Rivet

TITLE
Director
COMPENSATION
$266K
AGE
70
TENURE
3.3 yrs

W. Austen

TITLE
Director Emeritus
COMPENSATION
$255K
AGE
88
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
15. Feb 19 Sell Martin Sutter Individual 13. Feb 19 15. Feb 19 -20,000 $361.00 $-7,203,110
06. Feb 19 Sell Martin Sutter Individual 04. Feb 19 06. Feb 19 -30,000 $351.46 $-10,502,635
X
Management checks
We assess ABIOMED's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ABIOMED has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should You Be Pleased About The CEO Pay At ABIOMED, Inc.'s (NASDAQ:ABMD)

First, this article will compare CEO compensation with compensation at other large companies. … View our latest analysis for ABIOMED How Does Mike Minogue's Compensation Compare With Similar Sized Companies? … So Mike Minogue receives a similar amount to the median CEO pay, amongst the companies we looked at.

Simply Wall St -

Do ABIOMED's (NASDAQ:ABMD) Earnings Warrant Your Attention?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story stocks' without revenue, let alone profit. … But as Warren Buffett has mused, 'If you've been playing poker for half an hour and you still don't know who the patsy is, you're the patsy.' When they buy such story stocks, investors are all too often the patsy. … Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth.

Simply Wall St -

Is ABIOMED, Inc. (NASDAQ:ABMD) A Financially Strong Company?

(NASDAQ:ABMD), a large-cap worth US$12b, comes to mind for investors seeking a strong and reliable stock investment. … Most investors favour these big stocks due to their strong balance sheet and high market liquidity, meaning there are an abundance of stock in the public market available for trading. … These companies are resilient in times of low liquidity and are not as strongly impacted by interest rate hikes as companies with lots of debt.

Simply Wall St -

Is ABIOMED, Inc.'s (NASDAQ:ABMD) High P/E Ratio A Problem For Investors?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … We'll look at ABIOMED, Inc.'s (NASDAQ:ABMD) P/E ratio and reflect on what it tells us about the company's share price. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Who Has Been Selling ABIOMED, Inc. (NASDAQ:ABMD) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in ABIOMED, Inc. … The Last 12 Months Of Insider Transactions At ABIOMED. … Although we don't gain confidence from insider selling, we note that this large sale was at well above current price of US$283

Simply Wall St -

How To Gain With ABIOMED, Inc. (NASDAQ:ABMD)

When stock prices are falling, the best mindset to have is a long term one. … has fared well over time in a fickle stock market, which is why I want to bring it into light amongst all the chaos. … Below I take a look at three key features of what makes a robust defensive stock investment: its size, financial health and track record.

Simply Wall St -

Is ABIOMED, Inc. (NASDAQ:ABMD) Potentially Underrated?

As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook.

Simply Wall St -

Did You Miss ABIOMED's Magnificent 1039% Share Price Gain?

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. … During five years of share price growth, ABIOMED achieved compound earnings per share (EPS) growth of 92% per year. … This EPS growth is higher than the 63% average annual increase in the share price.

Simply Wall St -

ABIOMED, Inc. (NASDAQ:ABMD) Delivered A Better ROE Than Its Industry

This article is for those who would like to learn about Return On Equity (ROE). … That means that for every $1 worth of shareholders' equity, it generated $0.26 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is ABIOMED, Inc.'s (NASDAQ:ABMD) CEO Salary Justified?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big companies. … The aim of all this is to consider the appropriateness of CEO pay levels. … How Does Mike Minogue's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Company Info

Description

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Details
Name: ABIOMED, Inc.
ABMD
Exchange: NasdaqGS
Founded: 1981
$11,753,635,132
45,122,985
Website: http://www.abiomed.com
Address: ABIOMED, Inc.
22 Cherry Hill Drive,
Danvers,
Massachusetts, 01923,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ABMD Common Stock Nasdaq Global Select US USD 29. Jul 1987
DB AIO Common Stock Deutsche Boerse AG DE EUR 29. Jul 1987
LSE 0H7S Common Stock London Stock Exchange GB USD 29. Jul 1987
BMV ABMD * Common Stock Bolsa Mexicana de Valores MX MXN 29. Jul 1987
Number of employees
Current staff
Staff numbers
1,143
ABIOMED employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 01:26
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.